Department of Medicine, Kwame Nkrumah University of Science & Technology, Private Mail Bag, Kumasi, Ghana.
Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Curr Neurol Neurosci Rep. 2022 Nov;22(11):735-743. doi: 10.1007/s11910-022-01239-x. Epub 2022 Oct 1.
Worldwide, compared to other racial/ethnic groups, individuals of African ancestry have an excessively higher burden of hypertension-related morbidities, especially stroke. Identifying modifiable biological targets that contribute to these disparities could improve global stroke outcomes. In this scoping review, we discuss how pathological perturbations in the renin-angiotensin-aldosterone pathways could be harnessed via physiological profiling for the purposes of improving blood pressure control for stroke prevention among people of African ancestry.
Transcontinental comparative data from the USA and Ghana show that the prevalence of treatment-resistant hypertension among stroke survivors is 42.7% among indigenous Africans, 16.1% among African Americans, and 6.9% among non-Hispanic Whites, p < 0.0001. A multicenter clinical trial of patients without stroke in 3 African countries (Nigeria, Kenya, and South Africa) demonstrated that physiological profiling using plasma renin activity and aldosterone to individualize selection of antihypertensive medications compared with usual care resulted in better blood pressure control with fewer medications over 12 months. Among Ghanaian ischemic stroke survivors treated without renin-aldosterone profiling data, an analysis revealed that those with low renin phenotypes did not achieve any meaningful reduction in blood pressure over 12 months on 3-4 antihypertensive medications despite excellent adherence. For a polygenic condition such as hypertension, individualized therapy based on plasma renin-aldosterone-guided selection of therapy for uncontrolled BP following precision medicine principles may be a viable strategy for primary and secondary stroke prevention with the potential to reduce disparities in the poor outcomes of stroke disproportionately shared by individuals of African ancestry. A dedicated clinical trial to test this hypothesis is warranted.
与其他种族/民族相比,非洲血统的个体在高血压相关发病率方面,尤其是在中风方面,负担过重。确定导致这些差异的可改变生物学靶点,可能会改善全球中风结局。在本次范围综述中,我们讨论了肾素-血管紧张素-醛固酮系统的病理改变如何通过生理分析得以利用,以改善非洲血统个体的血压控制,从而预防中风。
来自美国和加纳的跨大陆比较数据显示,中风幸存者中治疗抵抗性高血压的患病率在非洲本土人中为 42.7%,在非裔美国人中为 16.1%,在非西班牙裔白人中为 6.9%,p<0.0001。在 3 个非洲国家(尼日利亚、肯尼亚和南非)进行的一项无中风患者的多中心临床试验表明,使用血浆肾素活性和醛固酮进行生理分析,以个体化选择降压药物,与常规治疗相比,可在 12 个月内更好地控制血压,同时减少药物用量。在未进行肾素-醛固酮分析数据的加纳缺血性中风幸存者中,一项分析显示,尽管药物依从性良好,但低肾素表型的患者在 12 个月内使用 3-4 种降压药物,血压没有任何明显降低。对于高血压等多基因疾病,基于血浆肾素-醛固酮指导的个体化治疗,根据精准医学原则选择治疗不受控制的血压,可能是一级和二级中风预防的可行策略,具有降低非洲血统个体中风不良结局不成比例的潜力。有必要进行专门的临床试验来检验这一假设。